Advanced Search

Psychiatric Services, VOL. 55, No. 3

Columns | March 01, 2004

Datapoints: Trends in Naltrexone Use Among Members of a Large Private Health Plan

Katherine M. Harris, Ph.D.; Andrea DeVries, Ph.D.; Kelli Dimidjian, M.B.A.

Psychiatric Services 2004; doi: 10.1176/appi.ps.55.3.221

Article

Figures

References

text A A A

Naltrexone was approved by the Food and Drug Administration in 1994 as an adjunct to psychosocial therapy for alcohol-dependent and alcohol-abusing patients. Clinical evidence suggests that when naltrexone is combined with psychosocial treatment models, it reduces the percentage of days that the patient drinks, reduces the alcohol consumed when the patient does drink, and prevents the patient from relapsing and drinking excessively and destructively (1). Guidelines recommend that patients use naltrexone daily for three to six months and up to 24 months on the basis of the patient's preference and compliance with treatment (1).

Despite evidence of naltrexone's effectiveness (1), use rates remain very low. Naltrexone is prescribed for less than 13 percent of patients who are undergoing treatment for alcohol dependence and abuse (2) and is prescribed regularly by less than 15 percent of addiction specialists (3).

To determine how the rate and duration of naltrexone use have changed over time, we analyzed paid claims for patients of a large mid-Atlantic health insurer with more than three million members who were taking naltrexone among the subpopulation of 1.5 million members who were 18 years or older and had prescription drug and behavioral health benefits provided through the health plan. We calculated the number of filled naltrexone prescriptions per 10,000 members and the total number of days that naltrexone was supplied per patient from 2000 to 2002.

Our data confirmed the low use rates and revealed no clinically meaningful trend toward increasing naltrexone use over time. Our data suggest that less than 10 percent of plan members who received alcohol treatment in any setting received naltrexone in any of the three study years.

Our data also suggest that a typical patient who initiates naltrexone treatment uses the medication for a substantially shorter period than the recommended guidelines and that trends in the duration of naltrexone use have not changed over time (Figure 1).

Existing research suggests that a lack of information, physicians' perceptions that naltrexone is ineffective, and a lack of marketing by the manufacturer help to explain the low rates of naltrexone use (2,3).

Dr. Harris is affiliated with the office of applied studies of the Substance Abuse and Mental Health Services Administration, 5600 Fishers Lane, Room 16-105, Rockville, Maryland 20857 (e-mail, kharris@samhsa.gov). Dr. DeVries and Mr. Dimidjian are with Highmark Blue Shield in Pittsburgh. Harold Alan Pincus, M.D., and Terri L. Tanielian, M.A., are editors of this column.

View Large | Download Slide(.ppt)
Add to My POL

Figure 1.: Trends in the total number of days that naltrexone was supplied among members of a large mid-Atlantic health insurer

References

Naltrexone and Alcoholism Treatment. Treatment Improvement Protocol no 28. Rockville, Md, US Department of Health and Human Services, Public Health Service, Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment, 1998

Mark TL, Kranzler HR, Song X: Understanding US addiction physicians' low rate of naltrexone prescription. Drug and Alcohol Dependence71:219—228, 2003[PubMed][CrossRef]

Thomas CP, Wallack SS, Lee S, et al: Research to practice: adoption of naltrexone in alcoholism treatment. Journal of Substance Abuse Treatment24:1—11, 2003[PubMed][CrossRef]

Download all saved figures as a .zip file.

View Large
Download Slide(.ppt)

Add to My POL

Figure 1.

Trends in the total number of days that naltrexone was supplied among members of a large mid-Atlantic health insurer

Mark TL, Kranzler HR, Song X: Understanding US addiction physicians' low rate of naltrexone prescription. Drug and Alcohol Dependence71:219—228, 2003[PubMed][CrossRef]

Thomas CP, Wallack SS, Lee S, et al: Research to practice: adoption of naltrexone in alcoholism treatment. Journal of Substance Abuse Treatment24:1—11, 2003[PubMed][CrossRef]

CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.

Submit a Comments

Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of JBJS editorial staff.

* = Required Field

Comment Author(s)*(if multiple authors, separate names by comma)

Example: John Doe

Affiliation & Institution*

Comment Title*

Comment*

Cancel

Print
PDF
E-mail

Recipient(s) will receive an email with a link (good for 72 hours) to 'Datapoints: Trends in Naltrexone Use Among Members of a Large Private Health Plan' and do not need to have Psychiatric Services account to access the content.
Your Name:*
Example: John Doe

Email Address:* CC Me:
Enter your valid email address. Example: jdoe@example.com

Recipient's Email Address:*
Separate multiple email address with semi-colons (up to 5).

Subject:* 's Psychiatric Services: 'Datapoints: Trends in Naltrexone Use Among Members of a Large Private Health Plan'
Subject for your email.

Message:
(Optional, message will truncate at 1000 characters)

Processing your request... Please Wait...

Copyright © in the material you requested is held by The American Psychiatric Association (unless otherwise noted). This email ability is provided as a courtesy, and by using it you agree that you are requesting the material solely for personal, non-commercial use, and that it is subject to The American Psychiatric Association's Terms of Use. The information provided in order to email this topic will not be used to send unsolicited email, nor will it be furnished to third parties. Please refer to The American Psychiatric Association's Privacy Policy for further information.

Copyright © American Psychiatric Association. All rights reserved.
Share
Get Citation

Katherine M. Harris, Andrea DeVries, Kelli Dimidjian; Datapoints: Trends in Naltrexone Use Among Members of a Large Private Health Plan. Psychiatric Services. 2004 Mar;55(3):221-221.

Download citation file:

RIS (Zotero)

EndNote

BibTex

Medlars

ProCite

RefWorks

Reference Manager

Copyright © American Psychiatric Association. All rights reserved.
Reprints